Axsome Therapeutics Announces AXS-07 Phase 3 Migraine Trial Results Selected by the American Academy of Neurology Science Committee as Featured Presentation
17 sept. 2020 07h00 HE
|
Axsome Therapeutics, Inc.
Data from MOMENTUM Phase 3 trial to be presented at the 2020 AAN Science Highlights Platform NEW YORK, Sept. 17, 2020 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a...
Axsome Therapeutics Completes Successful FDA Pre-NDA Meeting for AXS-07 for the Acute Treatment of Migraine
20 août 2020 07h00 HE
|
Axsome Therapeutics, Inc.
NDA submission on track for 4Q 2020 NEW YORK, Aug. 20, 2020 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management...
Axsome Therapeutics to Report Second Quarter 2020 Financial Results on August 10, 2020
30 juil. 2020 07h00 HE
|
Axsome Therapeutics, Inc.
Axsome to host conference call and webcast on Monday, August 10, 2020 at 8:00 AM Eastern Time NEW YORK, July 30, 2020 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a...
Axsome Therapeutics Reports First Quarter 2020 Financial Results and Provides Business Update
08 mai 2020 07h00 HE
|
Axsome Therapeutics, Inc.
Clinical successes highlight Axsome’s accelerated evolution into a leading CNS company Positive pivotal Phase 2/3 results for AXS-05 in Alzheimer’s disease agitation further deepen innovative...
Axsome Therapeutics Announces AXS-07 Achieves Both Co-Primary Endpoints and Prevents Migraine Pain Progression in the INTERCEPT Phase 3 Trial in the Early Treatment of Migraine
06 avr. 2020 06h00 HE
|
Axsome Therapeutics, Inc.
Achieved freedom from migraine pain in 33% of AXS-07 patients versus 16% for placebo at 2 hours (co-primary endpoint, p=0.002) Prevented progression of migraine pain beyond mild intensity in 74% of...
Migraine Drugs Market To Reach USD 3.51 Billion By 2026 | Reports And Data
24 févr. 2020 11h30 HE
|
Reports and Data
New York, Feb. 24, 2020 (GLOBE NEWSWIRE) -- According to the current analysis of Reports and Data, the global Migraine Drugs market was valued at USD 1.29 billion in 2018 and is expected to reach...
Axsome Therapeutics Completes Patient Enrollment in the INTERCEPT Phase 3 Trial of AXS-07 in the Early Treatment of Migraine
20 févr. 2020 07h00 HE
|
Axsome Therapeutics, Inc.
NEW YORK, Feb. 20, 2020 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...
Axsome Therapeutics Announces AXS-07 Achieves Co-Primary and Key Secondary Endpoints in MOMENTUM Phase 3 Migraine Trial in Patients with History of Inadequate Response
30 déc. 2019 06h15 HE
|
Axsome Therapeutics, Inc.
Demonstrated statistical significance on regulatory co-primary endpoints of pain freedom (p<0.001) and freedom from most bothersome symptom (p=0.002) at 2 hours, compared to placebo Demonstrated...
Trevena Presents Phase 1 Data on TRV250 for Acute Migraine at American College of Neuropsychopharmacology 2019 Annual Meeting
12 déc. 2019 07h00 HE
|
Trevena Inc.
Safety, tolerability, and PK profile support potential utility as a novel acute migraine treatment option CHESTERBROOK, Pa., Dec. 12, 2019 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a...
Neurodiagnostics Market To Reach USD 25.14 Billion By 2026 | Reports And Data
26 nov. 2019 10h24 HE
|
Reports and Data
New york, Nov. 26, 2019 (GLOBE NEWSWIRE) -- High prevalence of neurological disorders, adoption of novel diagnostic technology, product launches, increasing strategic developments such as...